CRSP at a glance
CRISPR Therapeutics AG (CRSP, SEC CIK 1674416) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on November 2, 2026, an 8-K current report on November 2, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), CRISPR Therapeutics AG (CRSP) reported revenue of $3.5 million (down 90.6% from FY2024) and a net loss of $581.6 million. Diluted EPS was -$6.47.
- As of September 30, 2026, 35 institutional investment managers tracked by SignalX reported holding CRISPR Therapeutics AG (CRSP) shares worth $1.9 billion in 13F-HR filings.
- In the last 90 days, CRSP insiders reported 0 open-market purchases ($0) and 7 open-market sales ($4.9M) on Form 4, a net sale of $4.9M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $3.5M
- −90.6% vs prior year
- Insiders · 90 days
- 0 buys · 7 sells
- Net −$4.9M
- 13F holders
- 35 funds
- $1.9B · −1 vs prior quarter
- Latest 8-K
- Nov 2, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Development and commercialization of transformative CRISPR/Cas9 gene-editing therapeutics for serious diseases including hemoglobinopathies, in vivo editing, CAR T therapies, and regenerative medicine
- New emphasis: First approved CRISPR-based therapy CASGEVY launched globally in 2023 for sickle cell disease and beta thalassemia, with ongoing pediatric trial expansions and targeted conditioning research
- Strategic shift: Increased focus on in vivo editing pipeline using proprietary SyNTase technology and LNP delivery to target liver and other tissues, alongside advancing siRNA programs via Sirius partnership
- Quantitative metric: CASGEVY approved in multiple countries, addressing an estimated 60,000 patients; pediatric pivotal studies show 100% efficacy in vaso-occlusive crisis and transfusion independence endpoints
- Noteworthy fact: CASGEVY is the world’s first approved CRISPR-based gene therapy, representing a major milestone and shifting CRISPR Therapeutics from R&D to commercial-stage biopharma firm
Risk Factors
- Regulatory risk: FDA final guidance "Human Gene Therapy Products Incorporating Human Genome Editing" issued January 2024 may require additional testing or data
- Macroeconomic threat: Increased CASGEVY development and commercialization costs starting 2025 exceed revenue share, impacting financial position
- Operational vulnerability: Dependence on third-party manufacturers and supply chain to establish clinical and commercial product supply capacity
- Competitive risk: Other gene editing firms' ex vivo/in vivo therapies may trigger additional FDA requirements delaying CRISPR Therapeutics’ programs
- Financial risk: Cash $1,975.8M as of Dec 31, 2025 sufficient for 24 months, but substantial capital raises required thereafter, diluting shareholders
Management Discussion & Analysis
- Operating cash flow used $345.0M in 2025 vs $142.8M in 2024, $202.2M increase due to timing of Vertex milestone payments
- Investing cash flow used $31.8M in 2025 vs $280.5M in 2024, improvement driven by marketable debt securities maturities in 2025
- Financing cash flow provided $426.0M in 2025 vs $332.0M in 2024, mainly from $397.3M ATM common shares sale and $27.7M stock option proceeds
- Outlook: Cash sufficient to fund operations 24 months; dependency on equity/debt financing; risks include volatile markets, regulatory approval uncertainties, and commercial execution
AI summary of the CRSP 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes to previously disclosed risk factors in the December 31, 2025 Form 10-K
- Continued business, financial condition, and operating-results exposure from previously disclosed risks
- Prior-quarter risk disclosures remain applicable through the quarter ended March 31, 2026
Management Discussion & Analysis
- Quarterly revenue $12.7M vs $0.0M YoY, primarily $12.3M deferred Vertex collaboration revenue
- Net loss $111.4M vs $106.4M YoY, operating loss $130.0M vs $132.1M
- R&D expense $71.9M vs $58.9M, worst cost increase external R&D $25.1M vs $14.9M
- Cash, equivalents and securities $2,276.6M; operating cash used $282.1M for nine months
- $585.4M net convertible-note proceeds; cash runway at least 24 months, additional financing expected for long-term development
AI summary of the CRSP 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026 announced
- Business highlights included alongside quarterly results
Item EX-99.1: Item EX-99.1
- CASGEVY revenue $99 million, up 30% quarter-over-quarter and nearly sixfold year-over-year, validating accelerating commercial adoption
- More than 750 patients initiated CASGEVY treatment worldwide, with approvals expanding to younger children in additional markets
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Andrew J. Silver appointed CFO, principal financial officer and principal accounting officer effective October 19, 2026
- Internal promotion strengthens continuity, leveraging Silver’s finance, accounting, treasury and reporting experience since joining in 2018
Item 2.02: Results of Operations and Financial Condition
- CRISPR Therapeutics reported financial results for quarter ended June 30, 2026
- Business highlights and detailed financial figures contained in furnished Exhibit 99.1
Item EX-99.1: Item EX-99.1
- CASGEVY revenue reached $76 million, up 78% quarter-over-quarter and 151% year-over-year, strengthening commercial validation
- FDA approval for patients aged 2 and older expands potential eligibility by approximately 5,500 SCD or TDT patients
AI summaries of CRSP 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CRSP
Don't miss the next CRSP filing
- Alerts as it files. A push when CRSP files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CRSP, by share count.
- Ask anything. An AI agent that reads every CRSP filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Kulkarni Samarth | G | Nov 17, 2026 | 100,000 | - |
| Sakhamuri Sivakesava | A | Nov 4, 2026 | 90,000 | - |
| Sakhamuri Sivakesava | A | Nov 4, 2026 | 40,000 | - |
| Kulkarni Samarth | A | Oct 26, 2026 | 57,500 | - |
| Patel Naimish | A | Oct 26, 2026 | 24,000 | - |
| Silver Andrew Jacob | A | Oct 26, 2026 | 9,000 | - |
| KASINGER JAMES R. | A | Oct 26, 2026 | 18,000 | - |
| KASINGER JAMES R. | A | Oct 26, 2026 | 9,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $37.3M | $3.5M |
| Operating Income | - | -$466.6M | -$664.6M |
| Net Income | -$153.6M | -$366.3M | -$581.6M |
| Op. Margin | - | -1250.4% | -18933.6% |
| Net Margin | - | -981.5% | -16569.8% |
| Balance Sheet | |||
| Total Assets | $2.2B | $2.2B | $2.3B |
| Equity | - | $1.9B | $1.9B |
| ROE | - | -19.0% | -30.3% |
| Per Share | |||
| EPS | $-1.94 | $-4.34 | $-6.47 |
| Cash Flow | |||
| Operating CF | - | -$142.8M | -$345.0M |
| CapEx | $9.5M | $1.9M | $914K |
Source: XBRL data in CRISPR Therapeutics AG (CRSP)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CRSP share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 35 | $1.86B |
| Q2 2026 | 36 | $1.92B |
| Q1 2026 | 33 | $1.63B |
| Q4 2025 | 33 | $1.80B |
| Q3 2025 | 34 | $2.32B |
| Q2 2025 | 34 | $1.59B |
| Q1 2025 | 27 | $826.7M |
| Q4 2024 | 21 | $775.3M |
- State Street Corp+672.4K (+16%)
- ARK Investment Management+595.9K (+6%)
- Bank of America Corp+584.2K (+51%)
- Prudential Financial+49.7K (+333%)
- Two Sigma Investments+27.4K (+1%)
- Citadel Advisors LLC−461.1K (-99%)
- D.E. Shaw & Co−374.9K (-42%)
- Millennium Management−290.4K (-76%)
- JPMorgan Chase & Co−145.7K (-34%)
- Wells Fargo & Co−69.6K (-26%)
- FMR LLC (Fidelity)−1.91M
- Equitable Holdings Inc−16.3K
- StoneX Group Inc.−4.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 253 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CRSP filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 6, 2026 | - | - | - |
| 8-K | Nov 2, 2026 | - | Analysis | - |
| 10-Q | Nov 2, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 28, 2026 | - | - | - |
| 4 | Oct 28, 2026 | - | - | - |
| 4 | Oct 28, 2026 | - | - | - |
| 4 | Oct 28, 2026 | - | - | - |
| 4 | Oct 21, 2026 | - | - | - |
| 4 | Oct 20, 2026 | - | - | - |
| 8-K | Oct 19, 2026 | - | Analysis | - |
| 4 | Oct 16, 2026 | - | - | - |
| 4 | Oct 15, 2026 | - | - | - |
| 4 | Oct 15, 2026 | - | - | - |
| 4 | Oct 8, 2026 | - | - | - |
| 4 | Sep 24, 2026 | - | - | - |
| 4 | Sep 21, 2026 | - | - | - |
| 4 | Sep 21, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 10-Q | Aug 3, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
CRSP SEC filings: frequently asked questions
Are CRSP insiders buying or selling?
In the last 90 days, CRISPR Therapeutics AG (CRSP) officers, directors and 10% owners reported no open-market purchases and 7 open-market sales worth $4.9 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CRSP stock?
As of September 30, 2026, the largest CRISPR Therapeutics AG (CRSP) holders among the 13F filers tracked by SignalX were ARK Investment Management ($556.3 million), BlackRock ($459.1 million), State Street Corp ($276.3 million), Two Sigma Investments ($111.5 million), Bank of America Corp ($96.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CRSP's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), CRISPR Therapeutics AG (CRSP) reported revenue of $3.5 million (down 90.6% from FY2024) and a net loss of $581.6 million. Diluted EPS was -$6.47. The figures come from the XBRL data in the 10-K.
What are the main risks in CRSP's latest 10-K?
In the 10-K filed February 12, 2026, CRISPR Therapeutics AG (CRSP) flagged: Regulatory risk: FDA final guidance "Human Gene Therapy Products Incorporating Human Genome Editing" issued January 2024 may require additional testing or data. Macroeconomic threat: Increased CASGEVY development and commercialization costs starting 2025 exceed revenue share, impacting financial position. (AI summary of the Risk Factors section.)
What did CRSP report in its latest 8-K?
CRISPR Therapeutics AG (CRSP) filed an 8-K on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026 announced.
What are the latest CRSP SEC filings?
CRISPR Therapeutics AG (CRSP) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on November 2, 2026, an 8-K current report on November 2, 2026 and a Form 4 insider filing on November 19, 2026.
What is CRSP's SEC CIK number?
CRISPR Therapeutics AG (CRSP)'s SEC Central Index Key (CIK) is 1674416. EDGAR lists every CRSP filing under that number.
Ask anything about CRSP
The research agent reads CRSP's filings, financials, insider trades and 13F holders, then answers with sources.